Evidence map›Paper›PMID 34918105›Full record

ArticleJournal of molecular cell biology2022

Cancer-derived C-terminus-extended p53 mutation confers dominant-negative effect on its wild-type counterpart.

Shibo Huang, Bo Cao, Jieqiong Wang, Yiwei Zhang, Elisa Ledet, Oliver Sartor, Yuqin Xiong, Shelya X Zeng, Hua Lu

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of molecular cell biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 78% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Shibo HuangInstitute of Clinical Pharmacology, Nanchang University, Nanchang 330006, China.
Bo CaoDepartment of Biochemistry & Molecular Biology, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Jieqiong WangDepartment of Biochemistry & Molecular Biology, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Yiwei ZhangDepartment of Biochemistry & Molecular Biology, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Elisa LedetTulane Cancer Center, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Oliver SartorTulane Cancer Center, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Yuqin XiongInstitute of Clinical Pharmacology, Nanchang University, Nanchang 330006, China.
Shelya X ZengDepartment of Biochemistry & Molecular Biology, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Hua LuDepartment of Biochemistry & Molecular Biology, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Tulane University · USNanchang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The vast majority of p53 missense mutants lose the wild-type (wt) function and/or exert 'dominant-negative' effects on their wt counterpart. Here, we identify a novel form of p53 mutation with an extended C-terminus (p53 long C-terminus, p53LC) in a variety of human cancers. Interestingly, the two representative mutants (named 'p53-374*48' and 'p53-393*78') as tested in this study show both loss-of-function and dominant-negative phenotypes in cell proliferation and colony formation assays. Mechanistically, p53LCs interact with and retain wt p53 in the cytoplasm and prevent it from binding to the promoters of target genes, consequently inhibiting its transcriptional activity. Also, p53LCs are very stable, though not acetylated in cells. Remarkably, the p53LCs can desensitize wt p53-containing cancer cells to p53-activating agents. Together, our results unveil a longer form of p53 mutant that possesses a dominant-negative effect on its wt counterpart, besides losing its wt activity.

Indexed as

NeoplasmsHumansMutationPromoter Regions, GeneticTumor Suppressor Protein p53TP53 protein, humanTumor Suppressor Protein p53acetylationdominant-negative effectdrug resistancelonger C-terminus p53mutant p53-374*48mutant p53-393*78p53

Identifiers

PMID34918105
PMCPMC8964174
OpenAlexW4200143105

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.